Screening criteria set for Swedish pre-school children needs to change

Article

A Swedish initiative for screening the vision of six-years olds has found that those with a visual acuity (VA) of 0.65 rarely have defects that require treatment, making the current criterion of 0.8 too demanding on the available resources.

A Swedish initiative for screening the vision of six-years olds has found that those with a visual acuity (VA) of 0.65 rarely have defects that require treatment, making the current criterion of 0.8 too demanding on the available resources, according to a report published in the June issue of Acta Ophthalmologica Scandinavia.

Anna-Lena Hård from the Institute of Neuroscience and Physiology at Gothenburg University, Gothenburg, Sweden evaluated the new vision screening methods with particular attention to screening criteria. The current requirements state that, pre-school children with a VA <0.8 or symptoms, should be referred to eye clinics for VA testing, cover testing, cycloplegic autorefraction and ophthalmoscopy. The current screening limit of 0.8 was evaluated in relation to a limit of 0.65.

A total of 3,885 pupils underwent screening. Of these, 225 (6.6%) were referred and 236 underwent ophthalmological examination. Seventy-five percent of these were children with a VA of 0.65 in the worse eye and more than half of these were found, by the clinic, to have a VA of ≥0.8. Only 6.7% were found to have significant ammetropia.

Hård concluded that the current screening and referral criterion of 0.8 is too high, since most children with a VA of 0.65 rarely have defects requiring treatment.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.